Skip to main content
. 2009 Oct 14;7:111. doi: 10.1186/1477-7827-7-111

Table 4.

Pregnancy outcomes of the 865 ICSI cycles.

hMG
(n = 299)
HP-hMG
(n = 330)
r-hFSH
(n = 236)
p value
Clinical pregnancy per initiated cycle, n (%) 106 (35.5) 132 (40.0) 82 (34.7) 0.35
 ≤35 years 84 (39.4) 94 (47.5) 59 (41.5) 0.24
 >35 years 22 (25.6) 38 (28.8) 23 (24.5) 0.74
Implantation rate, % (± SD) 16 (24) 20 (27) 16 (23) 0.18
 ≤35 years 17 (25) 24 (29) 20 (25) 0.15
 >35 years 11 (21) 12 (21) 9 (17) 0.61
Ectopic pregnancy, n (%) 1 (0.3) 6 (1.8) 2 (0.8) -
 ≤35 years 1 3 1 -
 >35 years 0 3 1 -
Spontaneous abortion,*
n (%)
33 (31.1)a 25 (18.9)b 11 (13.4)c 0.009
(a vs b, c)
 ≤35 years 21 (25.0) 16 (17.0) 7 (11.9) 0.12
 >35 years 12 (54.5)a 9 (23.6)b 4 (17.3)c 0.01
(a vs b, c)
Live birth per initiated cycle, n(%) 73 (24.4) 107 (32.4) 71 (30.1) 0.09
 ≤35 years 63 (29.5) 78 (39.4) 52 (36.6) 0.08
 >35 years 10 (11.6) 29 (21.9) 19 (20.2) 0.21

Clinical pregnancy per initiated cycle, implantation, ectopic pregnancy and spontaneous abortion rates, and live birth per initiated cycle in 865 ICSI cycles with menotropin (hMG), highly-purified menotropin (HP-hMG) or follitropin alfa (r-hFSH) used for COH. Overall and age-stratified outcomes are presented.

*Spontaneous abortion rates are per clinical pregnancies.

COH, controlled ovarian hyperstimulation; hMG, human menopausal gonadotropin; HP-hMG, highly-purified hMG; ICSI, intracytoplasmic sperm injection; r-hFSH, recombinant human follicle-stimulating hormone; SD, standard deviation.